India’s largest pharmaceutical company, Sun Pharmaceutical Industries Ltd, reported a steady performance for the July-September quarter (Q2 FY26), posting a 2.6% year-on-year (YoY) rise in net profit to Rs 3,118 crore, compared to Rs 3,039 crore in the same period last year.
Sun Pharma Q2 Results FY2026: Net Profit Rises 2.6% YoY to Rs 3,118 Crore, Revenue Grows 8.9%
The company reported that its revenue for the quarter grew 8.9% year-on-year (YoY), reaching Rs 14,478 crore, as per its official filing with the stock exchange on Wednesday, November 5, 2025.
Sun Pharma Q2 Earnings: EBITDA Jumps 7.5%
The company’s EBITDA rose 7.5% to Rs 4,067 crore, while the EBITDA margin stood at 28.3%, down by 40 basis points from the previous year. The quarter’s growth was driven primarily by a strong performance in the India, Emerging Markets, and Rest of World (RoW) regions.
Strong India Performance Drives Growth
Sun Pharma’s India formulations business, its largest revenue contributor delivered a robust 11% YoY growth, with sales touching Rs 4,734.8 crore. This segment accounted for 32.9% of the company’s total consolidated revenue for the quarter. The company launched nine new products during the quarter and 15 products year-to-date, reinforcing its presence across therapeutic categories.
US Market Softens; Focus on Innovative Drugs
Sales from the United States, which form about 30.1% of total revenue, declined 4.1% YoY to $496 million (around Rs 4,410 crore). The dip in the generics segment was, however, partially offset by growth in the company’s innovative medicines portfolio. Notably, for the first time, sales of innovative drugs in the US surpassed those of generics, underscoring the company’s shift toward high-value, specialty-focused therapies.
Emerging Markets and RoW See Double-Digit Growth
In the Emerging Markets, Sun Pharma reported sales of $325 million (around Rs 2,890 crore), reflecting a 10.9% YoY increase, and contributing 19.7% to total consolidated revenue. Sales from the Rest of World (RoW) markets were $234 million (around Rs 2,080 crore), registering a 17.7% growth, and accounting for 14.2% of total revenue for the quarter.
Innovative Medicines Segment Continues Momentum
Sun Pharma’s Global Innovative Medicines segment, a high-margin business including treatments for psoriasis, alopecia, and other chronic conditions, posted strong growth of 16.4% YoY with sales of $333 million (around Rs 2,950 crore). This segment accounted for 20.2% of total consolidated revenue during Q2 FY26, underscoring the company’s strategy to expand its specialty and innovative product offerings globally.
API Segment Declines
External sales of Active Pharmaceutical Ingredients (API) dropped by 19.5% YoY to Rs 429.9 crore. Despite this decline, Sun Pharma maintained its focus on enhancing operational efficiency and strengthening its specialty portfolio.